Because RT-related outcome was known to be worse in p16− oropharyngeal cancer than p16+ [50], SOX2 needs to be further investigated as a candidate prognosticator to precisely select RT as a treatment option, especially in p16− OPSCC. This evidence concerns the gene CDKN2A and oropharynx cancer.